Market Intelligence

Neovance Commercial — sign in to continue

● BioMedTracker · liveRun: Jun 3, 2026
Pipeline
Launch Calendar
Hiring Signal
Exclusions
How Scoring Works
Sources
Qualified Pipeline — from BioMedTracker
From 926 raw catalysts to 703 qualified opportunities, tiered and routed to each rep.
926
Raw catalysts (BioMedTracker: PDUFA + NDA/BLA + Phase 3)
→
−223
Noise excluded (new indications, vaccines, biosimilars, suspended, out-of-scope)
→
703
Qualified & scored
→
53
Priority Pursue — focused rep outreach
Dana
167
qualified assets
Steve
107
qualified assets
Amy
144
qualified assets
Open / unassigned
285
need an owner
Rep (owner) All Dana Steve Amy Open Stage All PDUFA NDA/BLA Phase 3
▼ Priority Pursue 53score ≥ 70 · ~12-mo launch sweet spot · pursue now
#Company / Asset · IndicationStageExpected · TimingScoreLoAOwner
1
Neuvivo, Inc
NP-001 · Amyotrophic Lateral Sclerosis (ALS)
Neurology RARE		 PDUFA
Apr 2027
SWEET SPOT — ~12 mo to lau
91
 80% Open
2
Incyte Corporation
povorcitinib · Hidradenitis Suppurativa
Dermatology RARE ASCOAXS		 NDA/BLA
Apr 2026
SWEET SPOT — ~12 mo to lau
86
 70% Steve
3
Arcellx, Inc.
Anito-cel · Multiple Myeloma (MM)
Oncology RARE ASCOAXS		 PDUFA
Jan 2027
approaching sweet spot
86
 96% Steve
4
Scholar Rock, LLC
Apitegromab · Spinal Muscular Atrophy
Metabolic RARE AXS		 PDUFA
Dec 2026
approaching sweet spot
85
 99% Dana
5
Takeda Pharmaceutical Co. Ltd.
rusfertide · Polycythemia Vera (PV)
Oncology RARE AXS		 PDUFA
Dec 2027
slightly early
84
 97% Dana
6
Alnylam Pharmaceuticals Inc.
ALN-REGN4 · Myasthenia Gravis (MG)
Autoimmune/immunology RARE AXS		 NDA/BLA
Mar 2026
SWEET SPOT — ~12 mo to lau
83
 61% Dana
7
BioMarin Pharmaceutical Inc.
Voxzogo · Achondroplasia
Endocrine RARE AXS		 PH3
Jun 2026
slightly early
83
 99% Amy
8
PTC Therapeutics, Inc.
Translarna · Duchenne Muscular Dystrophy (DMD)
Metabolic RARE AXS		 PDUFA
Mar 2027
SWEET SPOT — ~12 mo to lau
79
 74% Steve
9
Sangamo Therapeutics, Inc.
Giroctocogene Fitelparvovec · Hemophilia A
Hematology RARE AXS		 NDA/BLA
Oct 2026
slightly early
78
 77% Steve
10
Pharvaris B.V.
PHVS416 · Hereditary Angioedema (HAE)
Autoimmune/immunology RARE		 NDA/BLA
Jun 2026
SWEET SPOT — ~12 mo to lau
77
 66% Open
11
uniQure N.V.
AMT-130 · Huntington's Disease
Neurology RARE		 NDA/BLA
Mar 2026
SWEET SPOT — ~12 mo to lau
76
 29% Open
12
BridgeBio Pharma, Inc.
BBP-418 · Limb-Girdle Muscular Dystrophy (LGMD)
Metabolic RARE		 NDA/BLA
Jun 2026
SWEET SPOT — ~12 mo to lau
76
 63% Open
13
Incyte Corporation
Opzelura · Hidradenitis Suppurativa
Dermatology RARE ASCOAXS		 NDA/BLA
Apr 2026
SWEET SPOT — ~12 mo to lau
75
 68% Steve
14
Annexon, Inc.
tanruprubart · Guillain-Barré Syndrome
Autoimmune/immunology RARE		 NDA/BLA
Dec 2026
slightly early
75
 67% Open
15
Monopar Therapeutics Inc.
ALXN-1840 · Wilson's Disease
Metabolic RARE		 NDA/BLA
Apr 2026
SWEET SPOT — ~12 mo to lau
75
 58% Open
16
Sanofi
Venglustat · Gaucher's Disease
Metabolic RARE		 NDA/BLA
Jun 2026
SWEET SPOT — ~12 mo to lau
75
 58% Amy
17
Sanofi
Venglustat · Fabry's Disease
Metabolic RARE		 NDA/BLA
Jun 2026
SWEET SPOT — ~12 mo to lau
75
 58% Amy
18
Novartis AG
Pelabresib · Myelofibrosis (MF)
Oncology RARE		 NDA/BLA
Jul 2026
SWEET SPOT — ~12 mo to lau
74
 47% Dana
19
Cogent Biosciences, Inc.
bezuclastinib · Mastocytosis
Autoimmune/immunology RARE		 PDUFA
Dec 2026
approaching sweet spot
74
 96% Dana
20
Intellia Therapeutics, Inc.
Nex-z · Hereditary Transthyretin (hATTR) Amyloidosis With Polyneuropathy (Familial Amyloid Polyneuropathy)
Metabolic RARE		 PH3
Jun 2026
slightly early
74
 61% Open
21
Incyte Corporation
povorcitinib · Hidradenitis Suppurativa
Dermatology RARE ASCOAXS		 PH3
Apr 2026
slightly early
74
 70% Steve
22
TMRC Co., Ltd.
Amnolake · Myelodysplastic Syndrome (MDS)
Oncology RARE		 NDA/BLA
Jul 2026
SWEET SPOT — ~12 mo to lau
73
 44% Open
23
Novartis AG
ianalumab · Sjogren's Disease
Autoimmune/immunology RARE		 NDA/BLA
Dec 2026
slightly early
73
 69% Dana
24
Ocugen Inc.
OCU400 · Retinitis Pigmentosa (RP) (Ophthalmology)
Ophthalmology RARE		 PH3
Jun 2026
slightly early
73
 — Steve
25
Ocugen Inc.
OCU400 · Retinitis Pigmentosa (RP) (Ophthalmology)
Ophthalmology RARE		 PH3
Jun 2026
slightly early
73
 — Steve
26
BridgeBio Pharma, Inc.
Encaleret · Autosomal dominant hypocalcemia with hypercalciuria (ADHH)
Metabolic RARE		 NDA/BLA
Jun 2026
SWEET SPOT — ~12 mo to lau
73
 — Open
27
Belite Bio, Inc.
tinlarebant · Stargardt Disease (Ophthalmology)
Ophthalmology RARE		 NDA/BLA
Jun 2026
SWEET SPOT — ~12 mo to lau
73
 51% Open
28
Rezolute, Inc.
RZ-358 · Congenital Hyperinsulinism (CHI)
Endocrine RARE		 NDA/BLA
Dec 2026
slightly early
73
 59% Dana
29
Rezolute, Inc.
RZ-358 · Congenital Hyperinsulinism (CHI)
Endocrine RARE		 PH3
Mar 2026
slightly early
73
 59% Dana
30
INmune Bio, Inc.
CORDStrom · Epidermolysis Bullosa
Metabolic RARE		 PH3
Mar 2026
slightly early
73
 58% Open
31
BioNTech SE
DB-1303 · Uterine (Endometrial) Cancer
Oncology RARE		 NDA/BLA
Dec 2026
slightly early
72
 — Dana
32
Actuate Therapeutics, Inc.
elraglusib · Pancreatic Cancer
Oncology RARE		 NDA/BLA
Mar 2026
SWEET SPOT — ~12 mo to lau
72
 11% Open
33
Novo Nordisk A/S
CagriSema · Diabetes Mellitus, Type II
Endocrine		 NDA/BLA
Mar 2026
SWEET SPOT — ~12 mo to lau
72
 57% Open
34
Alnylam Pharmaceuticals Inc.
ALN-REGN4 · Myasthenia Gravis (MG)
Autoimmune/immunology RARE AXS		 PH3
Mar 2026
slightly early
71
 61% Dana
35
AbbVie Inc.
Sura-vec · Wet Age-Related Macular Degeneration (Wet AMD) (Ophthalmology)
Ophthalmology		 NDA/BLA
Jun 2026
SWEET SPOT — ~12 mo to lau
71
 55% Open
36
Novartis AG
CPK850 · Retinitis Pigmentosa (RP) (Ophthalmology)
Ophthalmology RARE		 NDA/BLA
Dec 2026
slightly early
71
 — Dana
37
Roche Holding AG
RG6179 · Uveitis (Ophthalmology)
Ophthalmology RARE		 NDA/BLA
Dec 2026
slightly early
71
 51% Amy
38
Mirum Pharmaceuticals, Inc.
brelovitug · Hepatitis D (HDV) (Antiviral)
Infectious Disease RARE		 PH3
Jun 2026
slightly early
71
 64% Steve
39
Ionis Pharmaceuticals, Inc.
ION-373 · Neurology - Other
Neurology		 NDA/BLA
Mar 2026
SWEET SPOT — ~12 mo to lau
71
 46% Amy
40
Mesoblast Limited
Revascor · Chronic Heart Failure - Reduced Ejection Fraction (Chronic HFrEF)
Cardiovascular		 NDA/BLA
Mar 2026
SWEET SPOT — ~12 mo to lau
70
 44% Amy
41
Johnson & Johnson
Imaavy · Autoimmune Hemolytic Anemia (AIHA)
Hematology RARE		 NDA/BLA
Jun 2027
early — Tier 2 timing
70
 93% Steve
42
Eli Lilly and Company
Ixo-vec · Wet Age-Related Macular Degeneration (Wet AMD) (Ophthalmology)
Ophthalmology		 NDA/BLA
Jul 2026
SWEET SPOT — ~12 mo to lau
70
 52% Open
43
AstraZeneca PLC
efzimfotase alfa · Hypophosphatasia
Endocrine RARE		 PH3
Jun 2026
slightly early
70
 57% Dana
44
AstraZeneca PLC
efzimfotase alfa · Hypophosphatasia
Endocrine RARE		 PH3
Jun 2026
slightly early
70
 57% Dana
45
AstraZeneca PLC
efzimfotase alfa · Hypophosphatasia
Endocrine RARE		 PH3
Jun 2026
slightly early
70
 57% Dana
46
Novo Nordisk A/S
CagriSema · Obesity
Metabolic		 PDUFA
Dec 2026
approaching sweet spot
70
 97% Open
47
Moleculin Biotech, Inc.
naxtarubicin · Acute Myelogenous Leukemia (AML)
Oncology RARE		 PH3
Mar 2026
slightly early
70
 44% Open
48
Geron Corporation
Rytelo · Myelofibrosis (MF)
Oncology RARE		 PH3
Jun 2026
slightly early
70
 44% Steve
49
Moleculin Biotech, Inc.
naxtarubicin · Acute Myelogenous Leukemia (AML)
Oncology RARE		 PH3
Jun 2026
slightly early
70
 44% Open
50
Moleculin Biotech, Inc.
naxtarubicin · Acute Myelogenous Leukemia (AML)
Oncology RARE		 PH3
Jun 2026
slightly early
70
 44% Open
51
Oncolytics Biotech, Inc.
pelareorep · Pancreatic Cancer
Oncology RARE		 PH3
Mar 2026
slightly early
70
 43% Open
52
Oncolytics Biotech, Inc.
pelareorep · Pancreatic Cancer
Oncology RARE		 PH3
Mar 2026
slightly early
70
 43% Open
53
Oncolytics Biotech, Inc.
pelareorep · Pancreatic Cancer
Oncology RARE		 PH3
Jun 2026
slightly early
70
 43% Open
▶ Monitor 431score 48–69 · track, engage as timing nears
▶ Deprioritized 219score < 48 · low fit/timing
Launch Calendar — next 24 months
Every qualified asset on a single timeline. The shaded band is the 6–12 month engagement sweet spot. Click a month to see its assets.
Priority PursueOther qualifiedEngagement sweet spot (6–12 mo)
Assets launching in the sweet spot
Hiring & conference signals
Priority Pursue accounts (top 10) + hub competitors. Hiring spikes and Director+ access roles signal launch build-out; ASCO 2026 + Asembia AXS26 track where PP accounts show up.
Priority Pursue pipeline — top 10 by score

Neuvivo, Inc · score 91 · NP-001 ● MED

—
roles (scan pending)
pre-launch
trend
1 Exec
Top PP account. FDA Type C alignment on NDA path; Phase 3 targeted 2026; board expansion (Curnutte, Baffi). No public patient-access job board yet — commercial build likely ahead of trial start.
Neuvivo site · FDA path PR

Incyte Corporation · score 86 · povorcitinib ● HIGH

—
roles (scan pending)
ASCO 2026
trend
1 Director+
Congress materials live for ASCO 2026. Commercial-stage oncology — watch for market access / patient services postings around launch window.
ASCO 2026 materials · Careers

Arcellx, Inc. · score 86 · Anito-cel ● HIGH

—
roles (scan pending)
Gilead integration
trend
1 Director+
Gilead completed Arcellx acquisition (Feb 2026); ASCO/EHA 2026 data planned for anito-cel ahead of commercial launch — expect access/hub scale-up.
Gilead acquisition · Arcellx

Scholar Rock, LLC · score 85 · Apitegromab ● HIGH

12
open roles · 30d
commercial prep
trend
1 Director+
Senior Director, Patient Marketing (US) posted for apitegromab launch. Careers via Lever; talent acquisition active — classic pre-launch access/marketing build.
Patient Marketing role · Careers

Takeda Pharmaceutical Co. Ltd. · score 84 · rusfertide ● MED

—
roles (scan pending)
field access
trend
1 Director+
Field Reimbursement Manager postings observed in market scans — established manufacturer maintaining US access field team.
FRM postings · Careers

Alnylam Pharmaceuticals Inc. · score 83 · ALN-REGN4 ● MED

—
roles (scan pending)
stable
trend
Mature rare-disease commercial org. Monitor for Director+ patient access / market access roles tied to new registrational readouts.
Careers

BioMarin Pharmaceutical Inc. · score 83 · Voxzogo ● MED

—
roles (scan pending)
stable
trend
Established rare-disease hub model. Watch for US access leadership churn or expansion around lifecycle indications.
Careers

PTC Therapeutics, Inc. · score 79 · Translarna ● LOW

—
roles (scan pending)
stable
trend
No fresh access-leadership spike in last 30d scan. Continue weekly refresh against careers + LinkedIn.
Careers

Sangamo Therapeutics, Inc. · score 78 · Giroctocogene Fitelparvovec ● MED

—
roles (scan pending)
gene therapy
trend
Gene therapy launch path — hub and site-of-care roles typically precede approval. Monitor hematology congress + access hires.
Careers

Pharvaris B.V. · score 77 · PHVS416 ● LOW

—
roles (scan pending)
pre-US scale
trend
Emerging biotech — limited US access hiring visible publicly. Flag when VP Patient Services or hub roles appear.
Pharvaris
Hub competitors — 30-day role trend

CareMetx ● HIGH

52
open roles · 30d
+18 vs prior 30d
trend
3 Director+1 Exec
Senior Director + Director, Hub Operations open + FRM — leadership expansion after absorbing Cencora/Lash Group. Spike consistent with onboarding new manufacturer programs.
Director, Hub Operations · Field Reimbursement Manager · Careers

AssistRx ● HIGH

118
open roles · 30d
+12 vs prior 30d
trend
2 Director+1 Exec
118 open roles incl Director/VP Data Insights — high-volume hiring + senior data/insights build-out. Possible new program wins.
118 roles (LinkedIn) · Open positions (Glassdoor)

Valeris (PharmaCord + Mercalis/TrialCard) ● MED

58
open roles · 30d
new (post-merger)
trend
2 Director+
PharmaCord + Mercalis merged into Valeris — integration hiring. Watch for senior roles signaling program migration.
PharmaCord openings · Valeris
Conference signals — ASCO 2026 & Asembia AXS26 (top 10 PP)
ASCO = clinical presence / data readouts · Asembia = specialty pharmacy & market-access channel (Apr 26–30, Las Vegas). Status: confirmed · likely · watch.

Neuvivo, Inc · NP-001 · score 91

UNLIKELY ASCO Annual Meeting 2026 (May 29 – Jun 2, 2026) — NP-001 is ALS/neurology — not ASCO; watch AAN and neurology congresses.
WATCH Asembia AXS26 Summit (Apr 26 – 30, 2026) — Pre-Phase 3 / NDA path — no public access hiring yet; revisit if US launch team posts appear. source

Incyte Corporation · povorcitinib · score 86

CONFIRMED ASCO Annual Meeting 2026 (May 29 – Jun 2, 2026) — Congress materials page published for ASCO 2026 — active oncology portfolio presence. source
LIKELY Asembia AXS26 Summit (Apr 26 – 30, 2026) — Commercial-stage oncology manufacturer — high relevance for specialty pharmacy / access channel meetings pre-launch. source

Arcellx, Inc. · Anito-cel · score 86

CONFIRMED ASCO Annual Meeting 2026 (May 29 – Jun 2, 2026) — Gilead/Arcellx press: new ASCO and EHA 2026 data for anito-cel (RRMM) ahead of potential commercial launch. source
LIKELY Asembia AXS26 Summit (Apr 26 – 30, 2026) — Cell therapy launch prep — access, hub, and specialty pharmacy stakeholders converge at AXS. source

Scholar Rock, LLC · Apitegromab · score 85

UNLIKELY ASCO Annual Meeting 2026 (May 29 – Jun 2, 2026) — Apitegromab is SMA (neuromuscular) — not an ASCO-track asset; no published ASCO 2026 abstract found.
HIGH Asembia AXS26 Summit (Apr 26 – 30, 2026) — Pre-launch US commercial build (Patient Marketing, access-facing hires) — strong fit for specialty pharmacy summit. source

Takeda Pharmaceutical Co. Ltd. · rusfertide · score 84

WATCH ASCO Annual Meeting 2026 (May 29 – Jun 2, 2026) — Rusfertide (polycythemia vera) is hematology — monitor ASCO/ASH abstract releases; established manufacturer often presents. source
LIKELY Asembia AXS26 Summit (Apr 26 – 30, 2026) — Large commercial org with active US field reimbursement hiring — typical AXS attendee profile. source

Alnylam Pharmaceuticals Inc. · ALN-REGN4 · score 83

WATCH ASCO Annual Meeting 2026 (May 29 – Jun 2, 2026) — Monitor ASCO 2026 releases for oncology/rare overlap programs. source
LIKELY Asembia AXS26 Summit (Apr 26 – 30, 2026) — Rare/specialty portfolio with recurring access complexity — channel summit relevance. source

BioMarin Pharmaceutical Inc. · Voxzogo · score 83

UNLIKELY ASCO Annual Meeting 2026 (May 29 – Jun 2, 2026) — Voxzogo / rare metabolic — outside ASCO core; watch disease-specific congresses.
LIKELY Asembia AXS26 Summit (Apr 26 – 30, 2026) — Established rare-disease commercial model — specialty distribution and hub partners attend AXS. source

PTC Therapeutics, Inc. · Translarna · score 79

UNLIKELY ASCO Annual Meeting 2026 (May 29 – Jun 2, 2026) — Translarna / rare neuro — not ASCO-primary.
LIKELY Asembia AXS26 Summit (Apr 26 – 30, 2026) — Rare disease commercial footprint — access channel engagement expected. source

Sangamo Therapeutics, Inc. · Giroctocogene Fitelparvovec · score 78

WATCH ASCO Annual Meeting 2026 (May 29 – Jun 2, 2026) — Gene therapy / hemoglobinopathies — monitor hematology-oncology abstract lists. source
LIKELY Asembia AXS26 Summit (Apr 26 – 30, 2026) — Gene therapy access and hub readiness — relevant AXS audience. source

Pharvaris B.V. · PHVS416 · score 77

UNLIKELY ASCO Annual Meeting 2026 (May 29 – Jun 2, 2026) — HAE / rare immunology — not ASCO-core.
WATCH Asembia AXS26 Summit (Apr 26 – 30, 2026) — Emerging biotech pre-US scale — monitor for access leadership hires before AXS. source
Exclusions — repeatable hard rules
223 of 926 rows hard-excluded from the loaded export. Ty's manual process also soft-cuts via scoring (~400 target) — expand Pipeline data flow below.

Hard rules (automated)

Applied on every build_bmt.py run. Driven by BioMedTracker fields — not manual spreadsheet flags.
RuleTy mappingFieldMatchBMT columnCount
Non-NME — likely new indication of a marketed productTy bucket 1 · new indication of marketed drugclsNon-NMEClassification108
Biosimilar/generic — not supportedTy bucket 2 · generics / biosimilarsclsBiosimilarClassification7
Vaccine — different access model (out of scope)Ty bucket 3 · vaccines / different access modelclsVaccineClassification54
Out of scope (primary-care / non-specialty)Ty bucket 3 · primary-care / AZ-pack styledisease + rareinfectious disease or allergy; Rare ≠ YesDisease Group + Rare Disease41
Suspended/terminated programDead programphaseSuspended or TerminatedProgram Phase13
Company blacklist — *Ty / Bruce manual suppressblacklist.jsonactive entry match on companyCompany blacklist file0

Not used for auto-exclude (today): analysis notes (rep context only) · vendor (directional, never scored) · timing/fit scores (tier down, not hard-cut) · respiratory primary-care (18 still qualified — score penalty only).

Company blacklist

Edit build/blacklist.json — set active: true to enforce on next rebuild. Illustrative until Ty confirms.
CompanyReasonRevisitStatusNotes
[ Example — Recent RFP loss ]Recent RFP loss — illustrative2031-06illustrativeReplace with real manufacturer name; set active=true
[ Example — Competitor won program ]Competitor holds hub contract — illustrative2028-06illustrativeSuppress until contract renewal window
[ Example — Never pursue ]Neovance policy — illustrative—illustrativePermanent block; confirm with Ty before activating

Excluded this run — by bucket (223)

Expand each bucket for examples with the fields that triggered the rule.
▼Non-NME — likely new indication of a marketed product108
Examples from loaded export — matched on BioMedTracker fields above.
Ascendis Pharma A/S — Yuviwel (Achondroplasia) PDUFA cls: Non-NME · phase: Approved · Endocrine RARE
Hope Therapeutics, Inc. — NRX-100 (Major Depressive Disorder (MDD)) PDUFA cls: Non-NME · phase: NDA · Psychiatry
Auzone Biological Technology Pty Ltd — Aukontals (Amyotrophic Lateral Sclerosis (ALS)) PDUFA cls: Non-NME · phase: NDA · Neurology RARE
Laboratorios Salvat, S.A. — SVT-15473 (Postsurgical Pain) PDUFA cls: Non-NME · phase: NDA · Neurology
Medicus Pharma Ltd. — D-MNA (Skin Cancer - Basal Cell Carcinoma (BCC)) PDUFA cls: Non-NME · phase: II · Oncology
Unicycive Therapeutics, Inc. — Renazorb (Hyperphosphatemia) PDUFA cls: Non-NME · phase: NDA · Renal
+ 102 more in this bucket
▶Vaccine — different access model (out of scope)54
▶Out of scope (primary-care / non-specialty)41
▶Suspended/terminated program13
▶Biosimilar/generic — not supported7
▶Time-based rules (planned — not wired yet)S-004
▶Pipeline data flow926 → 703
How Scoring Works
Timing-led, not therapy-gated. Every account gets a transparent 0–100 composite.
DimensionWeightWhat it measuresInputs (BioMedTracker)
Launch Timing45%Most important. Peaks ~12 months to launch — the outreach sweet spot. Penalizes already-approved ("missed the boat") AND 24+ months out ("too early, too many variables").Expected End Date by stage (PDUFA→approval, NDA/BLA→+~12mo, Phase 3→+~20mo)
Service Fit30%How HUB-dependent. Rare/specialty + injectable/infused weigh up; primary-care weighs down.Rare Disease, Disease Group, Route of Administration
Access Difficulty25%Prior-auth / specialty-distribution burden.Route, rare status, designations (orphan)
Likelihood of Approval×confConfidence multiplier (0.7–1.0). A 99% LoA asset is de-risked; a 30% LoA asset is dampened.BioMedTracker LoA %
Competitive overlayflagDirectional only — shown, not scored. Hub vendor is rarely published (~50% accurate) and differs from the pharmacy-dispensing vendor.Current Vendor (only 10 of 703 populated)

Tiers: Priority Pursue ≥ 70 · Monitor 48–69 · Deprioritized < 48. Composite = (0.45 Timing + 0.30 Fit + 0.25 Access) × LoA confidence.

Timing leads and penalizes already-approved assets; therapy area is not a gate; Likelihood of Approval is folded in as a confidence multiplier; competitive/hub intel is a directional flag, never scored.

Sources & Data Inputs
Every layer that feeds the Market Intelligence dashboard — primary pipeline, enrichment APIs, public intel, and local data files the reps actually see.

1 · Primary pipeline — BioMedTracker (paid)

Source of truth for the qualified pipeline. Bruce's team exports monthly; we re-score on each refresh.
InputDetail
Export file"PDUFA NDA BLA PH3" — 926 raw catalysts (PDUFA + NDA/BLA filed + Phase 3)
Fields usedCompany, drug, indication, disease group, rare flag, phase, Likelihood of Approval %, classification (NME/biologic/etc.), route, designations, partner, owner (BDD), Current Vendor, analysis notes
Output in tool703 qualified · 53 Priority Pursue · scored tiers · rep routing · one-pager analysis text
Not used forDeal tracking (Salesforce only) · live CRM workflow

2 · Contact & org intelligence — Exa.ai

Exa enriches decision-makers and org structure. Results are written to local JSON — the dashboard never calls Exa at view time. Cache tracked in exa_cache_manifest.json.
Exa surfaceUseCadence
Search API (category: people)Batch bucket searches → bucket by employer → contacts.json + org_maps.jsonWeekly (cache-aware)
MCP (web_search_advanced_exa)Interactive gap fills (e.g. TMRC, Scholar Rock deep map)On demand only
Websets MonitorsStanding people lists + competitor hiring/news with dedup (planned)Weekly / bi-weekly

Scheduled bucket queries (exa_refresh.py):

Bucket IDExa query (people / news)TTL
rare_disease_biotech_accessVP Market Access OR Patient Services OR Field Reimbursement directors at rare disease biotech companies7d
large_pharma_oncology_accessExecutive Director OR VP Market Access oncology pharmaceutical United States14d
competitor_hiring_newsCareMetx OR AssistRx OR Valeris patient access hub operations director job opening7d

Title patterns we match (Market Access / Patient Services): VP & Head of US Market Access · Patient Access & Experience · National Patient Access · Field Reimbursement (Director/AD) · Chief Brand Officer / US GM · VP US Medical Affairs

Coverage today: 49 companies · 83 named contacts · 36 org maps (Option C MA/PSS + call order) · Scholar Rock = hand-built reference quality

3 · Public regulatory & clinical

SourceWhat we pullFeeds
FDA / Drugs.comPDUFA dates, approval status confirmationTiming validation (planned automation)
ClinicalTrials.govPhase, indication, sponsor trial detailEnrichment / verification (planned)

4 · Financial & runway

SourceWhat we pullFeeds
SEC EDGAR (10-Q / 10-K)Cash runway, R&D spend context for emerging biotechOne-pager layer (planned; Exa financial report category)

5 · Competitor & hub-vendor intel

Directional only — never scored. Hub vendor rarely published (~50% accurate when inferred).
CompetitorSources searchedSignal
CareMetxPaylocity careers, caremetx.com/careers, LinkedIn, Indeed, Exa news bucket52 roles / 30d · Director+ Hub Ops · post-Lash Group expansion
AssistRxLinkedIn jobs, Glassdoor, company site118 roles / 30d · Dir/VP Data Insights
Valeris (PharmaCord + Mercalis)ZipRecruiter, valeris.com, merger press58 roles / 30d · post-merger integration hiring

M&A context: CareMetx acquired Cencora/Lash Group (Apr 27, 2026); PharmaCord + Mercalis/TrialCard → Valeris.

6 · Local data layer (what the dashboard reads)

FileContents
data/*.xlsxRaw BioMedTracker export
bmt.json → bmt_scored.json / bmt_excluded.jsonParsed, scored, tiered pipeline
contacts.jsonFlat contacts per company (Exa-sourced LinkedIn URLs)
org_maps.jsonMA/PSS maps, call order, movement signals
Contact_Graph.jsonReusable cross-account contact graph
hiring.jsonPipeline PP + competitor hiring snapshots
conferences.jsonASCO 2026 + Asembia AXS26 signals for top PP accounts
exa_cache_manifest.jsonExa TTL / skip-duplicate-query tracker

7 · Refresh cadence

BioMedTracker export
Monthly (Bruce) → full re-score + funnel rebuild
Exa people buckets
Weekly cache-aware job (exa_refresh.py) — only stale buckets hit the API
Competitor hiring
Weekly · 30-day rolling role count · Director+ flagged
Net-new diff
Planned — show reps only what changed vs. prior run
Market Intelligence · BioMedTracker + Exa.ai + public regulatory, financial & hiring data · 703 qualified opportunities · updated Jun 5, 2026